Literature DB >> 22365609

TR-FRET-based duplex immunoassay reveals an inverse correlation of soluble and aggregated mutant huntingtin in huntington's disease.

Barbara Baldo1, Paolo Paganetti, Stephan Grueninger, David Marcellin, Linda S Kaltenbach, Donald C Lo, Martin Semmelroth, Andjelija Zivanovic, Dorothée Abramowski, Donna Smith, Gregor P Lotz, Gillian P Bates, Andreas Weiss.   

Abstract

Huntington's disease (HD) is an inherited neurodegenerative disorder caused by the amplification of a polyglutamine stretch at the N terminus of the huntingtin protein. N-terminal fragments of the mutant huntingtin (mHtt) aggregate and form intracellular inclusions in brain and peripheral tissues. Aggregates are an important hallmark of the disease, translating into a high need to quantify them in vitro and in vivo. We developed a one-step TR-FRET-based immunoassay to quantify soluble and aggregated mHtt in cell and tissue homogenates. Strikingly, quantification revealed a decrease of soluble mHtt correlating with an increase of aggregated protein in primary neuronal cell cultures, transgenic R6/2, and HdhQ150 knock-in HD mice. These results emphasize the assay's efficiency for highly sensitive and quantitative detection of soluble and aggregated mHtt and its application in high-throughput screening and characterization of HD models.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22365609     DOI: 10.1016/j.chembiol.2011.12.020

Source DB:  PubMed          Journal:  Chem Biol        ISSN: 1074-5521


  38 in total

Review 1.  Aggregation formation in the polyglutamine diseases: protection at a cost?

Authors:  Tiffany W Todd; Janghoo Lim
Journal:  Mol Cells       Date:  2013-06-19       Impact factor: 5.034

2.  Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients.

Authors:  Edward J Wild; Roberto Boggio; Douglas Langbehn; Nicola Robertson; Salman Haider; James R C Miller; Henrik Zetterberg; Blair R Leavitt; Rainer Kuhn; Sarah J Tabrizi; Douglas Macdonald; Andreas Weiss
Journal:  J Clin Invest       Date:  2015-04-06       Impact factor: 14.808

Review 3.  Polyglutamine Aggregation in Huntington Disease: Does Structure Determine Toxicity?

Authors:  Guylaine Hoffner; Philippe Djian
Journal:  Mol Neurobiol       Date:  2014-10-22       Impact factor: 5.590

4.  Identification of distinct conformations associated with monomers and fibril assemblies of mutant huntingtin.

Authors:  Jan Ko; J Mario Isas; Adam Sabbaugh; Jung Hyun Yoo; Nitin K Pandey; Anjalika Chongtham; Mark Ladinsky; Wei-Li Wu; Heike Rohweder; Andreas Weiss; Douglas Macdonald; Ignacio Munoz-Sanjuan; Ralf Langen; Paul H Patterson; Ali Khoshnan
Journal:  Hum Mol Genet       Date:  2018-07-01       Impact factor: 6.150

5.  Novel allele-specific quantification methods reveal no effects of adult onset CAG repeats on HTT mRNA and protein levels.

Authors:  Aram Shin; Baehyun Shin; Jun Wan Shin; Kyung-Hee Kim; Ranjit S Atwal; Jennifer M Hope; Tammy Gillis; John D Leszyk; Scott A Shaffer; Ramee Lee; Seung Kwak; Marcy E MacDonald; James F Gusella; Ihn Sik Seong; Jong-Min Lee
Journal:  Hum Mol Genet       Date:  2017-04-01       Impact factor: 6.150

6.  The Novel Alpha-2 Adrenoceptor Inhibitor Beditin Reduces Cytotoxicity and Huntingtin Aggregates in Cell Models of Huntington's Disease.

Authors:  Elisabeth Singer; Lilit Hunanyan; Magda M Melkonyan; Jonasz J Weber; Lusine Danielyan; Huu Phuc Nguyen
Journal:  Pharmaceuticals (Basel)       Date:  2021-03-12

7.  Identification of NUB1 as a suppressor of mutant Huntington toxicity via enhanced protein clearance.

Authors:  Boxun Lu; Ismael Al-Ramahi; Antonio Valencia; Qiong Wang; Frada Berenshteyn; Haidi Yang; Tatiana Gallego-Flores; Salah Ichcho; Arnaud Lacoste; Marc Hild; Marian Difiglia; Juan Botas; James Palacino
Journal:  Nat Neurosci       Date:  2013-03-24       Impact factor: 24.884

8.  Experimental models for identifying modifiers of polyglutamine-induced aggregation and neurodegeneration.

Authors:  Barbara Calamini; Donald C Lo; Linda S Kaltenbach
Journal:  Neurotherapeutics       Date:  2013-07       Impact factor: 7.620

9.  HTRF analysis of soluble huntingtin in PHAROS PBMCs.

Authors:  Miriam Moscovitch-Lopatin; Rachel E Goodman; Shirley Eberly; James J Ritch; H Diana Rosas; Samantha Matson; Wayne Matson; David Oakes; Anne B Young; Ira Shoulson; Steven M Hersch
Journal:  Neurology       Date:  2013-08-21       Impact factor: 9.910

10.  Transneuronal propagation of mutant huntingtin contributes to non-cell autonomous pathology in neurons.

Authors:  Eline Pecho-Vrieseling; Claus Rieker; Sascha Fuchs; Dorothee Bleckmann; Maria Soledad Esposito; Paolo Botta; Chris Goldstein; Mario Bernhard; Ivan Galimberti; Matthias Müller; Andreas Lüthi; Silvia Arber; Tewis Bouwmeester; Herman van der Putten; Francesco Paolo Di Giorgio
Journal:  Nat Neurosci       Date:  2014-07-13       Impact factor: 24.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.